Back to Journals Integrated Pharmacy Research and Practice Volume 14 Molecular Pharmacology of Glucagon-Like Peptide 1-Based Therapies in the Management of Type Two Diabetes Mellitus and Obesity Authors Alzahrani AM, Alshobragi GA, Alshehri AM, Alzahrani MS, Alshehri HA, Alzhrani RM, Basudan S, Alkatheeri AA, Almutairi SA, Alzahrani YA Received 12 November 2024 Accepted for publication 13 March 2025 Published 6 April 2025 Volume 2025:14 Pages 5972 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Professor Walid Al-Qerem Abdullah M Alzahrani, 1 3 Ghada A Alshobragi, 1 Abdullah M Alshehri, 1 Majed S Alzahrani, 1 Hasan A Alshehri, 1 Rami M Alzhrani, 4 Samah Basudan, 5 Ayed A Alkatheeri, 6 Salman A Almutairi, 7 Yahya A Alzahrani 2, 6 1 Pharmaceutical Care Department, Ministry of National GuardHealth Affairs, Jeddah, 22384, Saudi Arabia

Benefit 6: Reduces Chronic Inflammation Chronic inflammation underlies many illnesses, including autoimmune diseases, vector-borne illnesses like Lyme disease and co-infections, IBD, and lung conditions like asthma, COPD, cystic fibrosis
PMCID: PMC7891038
Keep your GLP-1, insulin, peptide, or TRT injection supplies organized and protected with this compact 3ml vial storage case
INS-1 832/3 and MIN6B1 cells were stimulated in serum-free media plus 3 mM glucose and IBMX as indicated, with results expressed relative to time-point-specific IBMX-only baseline